As of the latest available data, Johnson and Johnson's stock price has been fluctuating, recently trading at around one hundred sixty-five dollars and eighty-six cents per share. The trading volume has been notable, with over eight million one hundred nineteen thousand shares changing hands, which is a significant amount but still below the average session volume.
Recently, Johnson and Johnson reported strong fourth-quarter results for the year two thousand twenty-four, with sales growth of five point three percent, reaching twenty-two billion five hundred million dollars. This was driven by operational growth of six point seven percent, with notable contributions from its MedTech segment, particularly in electrophysiology and cardiovascular products.
In terms of recent news, Johnson and Johnson has been making strides in clinical trials, with its treatment for ulcerative colitis showing promising results. Additionally, the company has been involved in significant personnel moves, such as a former executive joining Pfizer to lead anti-obesity efforts.
Analysts have mixed views on Johnson and Johnson, with some maintaining a "buy" rating while others have reduced their target prices. For instance, Citigroup lowered its target price from one hundred eighty-five dollars to one hundred seventy-five dollars, while Bank of America raised its target to one hundred seventy-one dollars. Overall, Johnson and Johnson's stock has a moderate buy rating with a consensus target price around one hundred seventy-one dollars and thirty-three cents.
Despite recent performance improvements, Johnson and Johnson's stock has underperformed the broader market over the past year, though it has shown stronger returns in the short term. The company's market capitalization remains substantial, at approximately three hundred ninety-nine billion dollars.
For more http://www.quietplease.ai
Stock up on these deals
https://amzn.to/3QFpYIX
This content was created in partnership and with the help of Artificial Intelligence AI
